Gilead and Ferozsons’ Hepatitis C Access Program appreciated

A recent report published by leading business daily, the Business Recorder, appreciates the partnership between Ferozsons Laboratories Limited and Gilead Sciences Inc. to implement the Access Program for Hepatitis C Virus (HCV), offering the breakthrough treatment, Sovaldi in Pakistan at a fraction of its international cost.

Under the second phase of this access program, Ferozsons will now be manufacturing the first locally produced authorized generic of the drug Sovaldi at a highly reduced cost to reach an even larger number of patients in Pakistan.

The report suggests that access programs that bring innovative and breakthrough therapies to the developing countries should be encouraged by governments so they are able to reach to the most deserving patients in these countries. The report also mentions how, in the absence of insurance, co-payments and government funding, such interventions have the potential to save millions of lives.